ATI-450 vs Placebo in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2a study to investigate the efficacy, safety, tolerability, pharmacokinetics,
and pharmacodynamics of ATI-450 vs placebo in patients with moderate to severe Hidradenitis
Suppurativa (HS).